{"prompt": "['5.3.5.4', 'Persistent or Recurrent Adverse Events', '135', '5.3.5.5', 'Abnormal Laboratory Values', '135', '5.3.5.6', 'Abnormal Vital Sign Values', '136', '5.3.5.7', 'Abnormal Liver Function Tests', '136', '5.3.5.8', 'Deaths', '137', '5.3.5.9', 'Pre-existing Medical Conditions', '137', '5.3.5.10', 'Lack of Efficacy or Worsening of Hemophilia A', '137', '5.3.5.11', 'Hospitalization or Prolonged Hospitalization', '138', '5.3.5.12', 'Adverse Events Associated with an Overdose or Error in', 'Drug Administration', '138', '5.3.5.13 Patient-Reported Outcome Data', '138', '5.4', 'Immediate Reporting Requirements from Investigator to', 'Sponsor', '139', '5.4.1', 'Emergency Medical Contacts', '139', '5.4.2', 'Reporting Requirements for Serious Adverse Events and', 'Adverse Events of Special Interest', '139', '5.4.2.1', 'Events That Occur prior to Study Drug Initiation', '139', '5.4.2.2', 'Events That Occur after Study Drug Initiation', '140', '5.4.3', 'Reporting Requirements for Pregnancies', '140', '5.4.3.1', 'Pregnancies in Female Patients', '140', '5.4.3.2', 'Pregnancies in Female Partners of Male Patients', '140', '5.4.3.3', 'Abortions', '141', '5.4.3.4', 'Congenital Anomalies/Birth Defects', '141', '5.5', 'Follow-Up of Patients after Adverse Events', '141', '5.5.1', 'Investigator Follow-Up', '141', '5.5.2', 'Sponsor Follow-Up', '141', '5.6', 'Adverse Events That Occur after the Adverse Event', 'Reporting Period', '141', '5.7', 'Expedited Reporting to Health Authorities, Investigators,', 'Institutional Review Boards, and Ethics Committees', '142', '6. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN', '142', '6.1', 'Determination of Sample Size', '142', '6.2', 'Summaries of Conduct of Study', '143', '6.3', 'Summaries of Demographic and Baseline Characteristics', '143', '6.4', 'Safety Analyses', '143', '6.5', 'Efficacy Analyses', '144', 'Emicizumab - F. Hoffmann-La Roche Ltd', '72 / Protocol MO39129, Version 3']['6.6', 'Immunogenicity Analyses', '145', '6.7', 'Pharmacokinetic Analyses', '146', '6.8', 'Biomarker Analyses', '146', '6.9', 'Interim Analyses', '146', '6.9.1', 'Planned Interim Analyses', '146', '6.9.2', 'Optional Interim Analysis', '146', '7. DATA COLLECTION AND MANAGEMENT', '146', '7.1', 'Data Quality Assurance', '146', '7.2', 'Electronic Case Report Forms', '147', '7.3', 'Electronic Patient-Reported Outcome Data', '147', '7.4', 'Source Data Documentation', '148', '7.5', 'Use of Computerized Systems', '148', '7.6', 'Retention of Records', '148', '8. ETHICAL CONSIDERATIONS', '149', '8.1', 'Compliance with Laws and Regulations', '149', '8.2', 'Informed Consent', '149', '8.3', 'Institutional Review Board or Ethics Committee', '150', '8.4', 'Confidentiality', '150', '8.5', 'Financial Disclosure', '151', '9. STUDY DOCUMENTATION, MONITORING, AND', 'ADMINISTRATION', '151', '9.1', 'Study Documentation', '151', '9.2', 'Protocol Deviations', '151', '9.3', 'Site Inspections', '151', '9.4', 'Administrative Structure', '151', '9.4.1', 'Independent Data Monitoring Committee', '151', '9.5', 'Publication of Data and Protection of Trade Secrets', '152', '9.6', 'Protocol Amendments', '153', '9.7', 'Study Participant Survey', '153', '10. REFERENCES', '154', 'Emicizumab - F. Hoffmann-La Roche Ltd', '73 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}